MedWatch

Expert committee recommends new Novo Nordisk growth hormone for EU approval

Novo Nordisk has broken ground for marketing growth hormone somapacitan in the EU after EMA expert panel CHMP adopts positive opinion of the treatment.

Photo: Novo Nordisk / PR

Just under five months after Novo Nordisk secured a US Food and Drug Administration (FDA) approval for sending the once-weekly growth hormone Sogroya on the market the European Medicines Agency (EMA) also announces their positive assessment of the treatment.

At the Committee for Medicinal Products for Human use meeting in January, the group of experts passed an EMA recommendation to issue a marketing authorization for the drug as a treatment for adults.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Further reading

Related articles

Latest news

See all jobs